22 citations,
September 2015 in “Clinical lymphoma myeloma & leukemia/Clinical lymphoma, myeloma and leukemia” Recognizing and treating skin symptoms in essential thrombocythemia is crucial for patient quality of life.
15 citations,
March 2012 in “International journal of nanomedicine” Local injections of nanosized rhEPO can speed up skin healing and improve quality after deep second-degree burns.
13 citations,
January 2015 in “Stem cells international” Mesenchymal Stem Cells (MSCs) are promising for multiple therapies, but more research is needed to fully understand and optimize their use.
6 citations,
March 2016 in “Scandinavian journal of immunology” Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
June 2019 in “Poster presentations” Low dose methotrexate does not increase hair fall and may reduce it.
June 2013 in “Annals of the rheumatic diseases” Methotrexate dose has little effect on its toxicity when used with adalimumab for early rheumatoid arthritis.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
May 2023 in “Journal of Investigative Dermatology” Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.
7 citations,
January 2021 in “Journal of advanced pharmaceutical technology & research” The compound 16 from the Merremia peltata plant could potentially be a good treatment for hair loss (alopecia) due to its strong activity and favorable skin absorption.
3 citations,
June 2023 in “Journal of dermatological treatment” Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
26 citations,
October 2016 in “American journal of clinical dermatology” New treatments like JAK inhibitors show promise for reversing alopecia areata.
20 citations,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
7 citations,
August 2023 in “Journal of the American Academy of Dermatology” JAK inhibitors offer new hope for treating severe alopecia areata.
1 citations,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
1 citations,
November 2022 in “International journal of molecular sciences” Human fetal placental stromal cell injections speed up healing and improve skin and hair recovery after radiation damage.
1 citations,
January 2022 in “Journal of Dermatology and Dermatologic Surgery” A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.
October 2022 in “Cosmoderma” September 2022 in “Scientific Reports” September 2014 in “SciBX” JAK inhibitors may help treat alopecia areata and promote hair regrowth.
Alopecia Areata has no cure, treatments are limited, and the condition often recurs, but new therapies like JAK inhibitors show promise.
157 citations,
February 2016 in “Journal of the American Academy of Dermatology” A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
2 citations,
March 2022 in “Journal of Personalized Medicine” Personalized medicine is important for treating skin disorders, with new treatments and connections to hormones and genetics being explored.
16 citations,
August 2011 in “Annals of Allergy Asthma & Immunology” A woman with severe angioedema improved significantly after treatment with rituximab.